SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, especially accelerating AI-compute revenue, sparked analyst upgrades and a bullish response. Traders also debated whether growth justifies the valuation, with heavy capital spending and an approaching share unlock cited as potential risks; Tesla merger discussions remain speculative.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings report beat profit expectations, but softer forward revenue guidance and a reduced advertising outlookalongside slowing growthtriggered a sharp selloff and renewed analyst downgrades. Traders are split between viewing the drop as evidence of tougher competition and weaker growth, and calling it an overreaction that creates a buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly outlook was sharply raised on strong AI-server demand, with gross-margin expectations also improving, sparking a sharp rally. Traders largely welcomed the update and argued the stock is undervalued, while others questioned whether margins, cash flow and execution can sustain the gains.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the 80th-event trigger and final analysis of its Phase 3 REGAL trial of GPS in AML, with recent trading gains fueling speculation about a near-term update and a possible short squeeze. Bullish buyout and positive-data theories are prominent, but skeptics note that no catalyst or outcome is confirmed and the trial results remain uncertain.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs spectrum acquisition and plans to expand Starlink Mobile have fueled concern that it could challenge AT&T and other wireless carriers, contributing to a sharp telecom selloff. Traders debate whether the threat is meaningful or years away, with bulls calling the drop an overreaction and pointing to AT&Ts fiber network and dividend.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on preliminary Phase 1 azer-cel results in progressive multiple sclerosis, with traders viewing the early safety and efficacy signals as a potential pipeline expansion beyond BRIUMVI while emphasizing that the study is small and needs confirmation. BRIUMVIs longer-term and commercial data also feature in the discussion, alongside mixed reactions to the stocks lack of sustained momentum.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

FDA approval of ORLADEYO oral pellets is drawing attention, with traders viewing the easier-to-administer formulation as a possible way to reach more HAE patients and improve tolerability. Some see incremental commercial potential, while others doubt it will meaningfully affect the share price amid continued frustration with BCRXs underperformance and management.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Analyst downgrades citing lackluster October momentum are weighing on Chipotle shares as traders look ahead to earnings amid concerns about slowing sales and margins. The community is split between expecting further declines and viewing the selloff as a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Speculation about possible U.S. regulatory relief for compounded peptides is a dominant topic, with bullish traders viewing access as a potential growth opportunity and skeptics emphasizing that approval is uncertain. The debate plays out alongside frustration over repeated rallies fading at resistance, while Hims German expansion adds to the growth discussion.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkors strong quarterly results have been overshadowed by a softer-than-expected revenue outlook, alongside a broader semiconductor selloff. Traders are split between viewing the decline as an overreaction to near-term guidance and worrying about AI demand, expansion costs, and whether advanced-packaging growth will justify the investment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Post Holdings' Pet E-Commerce Growth Outpaces Brick-and-Mortar

POST is seeing e-commerce outpace other pet food channels as it pursues brand relaunches, premium private-label growth and cost savings.

SJM vs. CELH: Which Stock Should Value Investors Buy Now?

SJM vs. CELH: Which Stock Is the Better Value Option?

Can J.M. Smucker's Hostess Donettes Drive a Broader Recovery?

J.M. Smucker's Donettes posts double-digit U.S. retail growth, but a 7% drop in Sweet Baked Snacks sales highlights the challenges ahead of a broader recovery.


Earnings Growth & Price Strength Make Smucker (SJM) a Stock to Watch

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Why Smucker (SJM) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Buy 5 High-Flying Consumer Staples Stocks for a Stable Portfolio in Q4

CO, MO, LW, SJM and ELF have delivered over 20% YTD returns, backed by growth strategies and favorable earnings trends.


BGS Advances Portfolio Reshaping With Latest Brand Divestiture

BGS sells its B&M and Joan of Arc brands to cut debt, building on portfolio restructuring that lifted adjusted EBITDA and margins despite declining sales.


Can J.M. Smucker's Uncrustables Momentum Accelerate Further?

J.M. Smucker's Uncrustables gains momentum through strong consumer demand, product innovation and wider distribution, with added capacity supporting future growth.


Here's Why Smucker (SJM) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Smucker (SJM) is a Strong Growth Stock

The J. M. Smucker Co. engages in the manufacture and marketing of food and beverage products. It operates through the following segments: U.S. Retail Coffee, U.S. Retail Frozen Handheld and Spreads, U.S. Retail Pet Foods, and Sweet Baked Snacks. The U.S. Retail Coffee segment includes the domestic sales of Folgers, Dunkin’, and Café Bustelo branded coffee. The U.S. Retail Frozen Handheld and Spreads segment focuses on domestic sales of Smucker’s and Jif branded products. The U.S. Retail Pet Foods segment is involved in the domestic sales of Meow Mix, Milk-Bone, Pup-Peroni, and Canine Carry Outs branded products. The Sweet Baked Snacks segment refers to all domestic and foreign sales of Hostess and Voortman branded products in all channels. The company was founded by Jerome Monroe Smucker in 1897 and is headquartered in Orrville, OH.

J.M. Smucker Co.

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>J.M. Smucker climbed to nearly a three-year high of $134.85 after the company posted better-than-expected fiscal 2027 first-quarter results.&nbsp;</li><li>JPMorgan kept an ‘Overweight’ rating on Replimune and raised its price target to $21 from $20.&nbsp;</li><li>NeoGenomics secured expanded Medicare coverage for its RaDaR ST liquid biopsy test.&nbsp;</li></ul><p>J.M. Smucker Co. (SJM), Replimune Group (REPL) and NeoGenomics (NEO) hit fresh 52-week highs on Wednesday, fueled by company-specific catalysts. Improving volumes at Smucker, clinical momentum at Replimune and Medicare coverage for NeoGenomics’ cancer test gave investors fresh reasons to buy.&nbsp;</p><p>J.M. Smucker and NeoGenomics stocks gained over 4% and 3%, while Replimune stock climbed 0.5%.&nbsp;</p><h2 class="st-heading-2">J.M.&nbsp;Smucker Gains On Improving Volumes</h2><p><a href="https://stocktwits.com/symbol/SJM">J.M. Smucker stock</a> reached nearly a three-year high of $134.85 after the packaged-food company delivered stronger-than-expected first-quarter fiscal 2027 results. The performance prompted BTIG to increase its price target to $150 from $130 while keeping a ‘Buy’ rating.</p><p>The key signal for investors was a recovery in underlying product volumes. With Hostess excluded, each of Smucker’s operating businesses posted volume gains during the quarter. The company’s Q2 revenue of $2.2 billion and earnings of $3.24 both exceeded analysts' consensus expectations of $2.1 billion and $2.2 per share, respectively, according to Fiscal Ai data.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">Replimune Builds On Clinical Momentum</h2><p><a href="https://stocktwits.com/symbol/REPL">Replimune stock</a> climbed to an annual high of $15.99 as investors continued to respond to developments surrounding its cancer-treatment pipeline. JPMorgan raised its price target to $21 from $20 and maintained an ‘Overweight’ rating.</p><p>The firm pointed to support from key opinion leaders for the company’s approach to treating melanoma patients whose disease has stopped responding to PD-1 therapies. Replimune’s Tudriqev program has emerged as an important part of that opportunity as the company advances through major regulatory approvals.</p><p>Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">NeoGenomics Gets A Reimbursement Boost</h2><p><a href="https://stocktwits.com/symbol/NEO">NeoGenomics stock</a> also reached a new 52-week high of $17.45. The company received a Medicare coverage determination for its RaDaR ST liquid biopsy test, which is designed to help detect minimal residual disease and assess treatment response.</p><p>Medicare reimbursement could make it easier for physicians to include the test in cancer care. The decision could expand NeoGenomics' commercial opportunity by reducing a major hurdle to wider adoption by oncology practices. However, retail sentiment around the stock remained in ‘bearish’ territory.</p><p>So far this year, SJM, REPL and NEO stocks have gained between 33% and 63%.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anf-stock-is-on-fire-after-strong-q2-why-jefferies-still-sees-18-more-upside/cZY8mnGRJpO">ANF Stock Is On Fire After ‘Strong Q2’ — Why Jefferies Still Sees 18% More Upside</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, a hand holds a smartphone displaying the logo of The J.M. Smucker Company.

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?

Earnings, drug development, and healthcare reimbursement fueled the stock rallies. 

Neogenomics Inc.

Replimune Group Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$129.67
Prev Close	$127.07
Open	$128.44
Dividend Yield	4.49%
50-Day Moving Average	$122.88
Beta	0.08
Avg. Volume	1.33M
PE Ratio	60.80

52-Week High	$135.89
52-Week Low	$88.25
Market Capitalization	$13.85B
EPS (Annual)	-$1.30
Price to Book	2.41
Revenue Per Employee	$1.13M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SJM Fundamentals